Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 09, 2020 07:30 ET | Source: Otonomy, Inc.

Otonomy Provides Business Update Related to COVID-19 Pandemic

SAN DIEGO, April 09, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided a...
February 27, 2020 16:15 ET | Source: Otonomy, Inc.

Otonomy Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

Results from three clinical trials expected in 2020 including the Phase 3 trial of OTIVIDEX™ in Ménière’s diseaseCurrent capital funds operations into 2021 Conference call and webcast today at 4:30...
February 24, 2020 07:30 ET | Source: Otonomy, Inc.

Otonomy to Present at Two Upcoming Investor Conferences

SAN DIEGO, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
February 20, 2020 07:30 ET | Source: Otonomy, Inc.

Otonomy to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Corporate Update

SAN DIEGO, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
January 28, 2020 07:30 ET | Source: Otonomy, Inc.

Otonomy Presents Preclinical Results for GJB2 Gene Therapy Collaboration and Cisplatin Otoprotection Program

SAN DIEGO, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced...
January 23, 2020 07:30 ET | Source: Otonomy, Inc.

Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting

SAN DIEGO, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced...
January 09, 2020 07:30 ET | Source: Otonomy, Inc.

Otonomy Provides Corporate and Product Pipeline Update

Three programs with clinical trial results in 2020 including OTIVIDEX™ Phase 3 trial in Ménière’s disease Current capital funds operations into 2021 SAN DIEGO, Jan. 09, 2020 (GLOBE NEWSWIRE) --...
November 26, 2019 16:05 ET | Source: Otonomy, Inc.

Otonomy to Participate in Two Upcoming Investor Conferences

SAN DIEGO, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
November 05, 2019 16:13 ET | Source: Otonomy, Inc.

Otonomy Reports Third Quarter 2019 Financial Results and Provides Corporate Update

Results from three clinical trials expected in 2020 including the Phase 3 trial of OTIVIDEX™ in Ménière’s diseaseBroadest pipeline in neurotology field expanded to include gene therapy collaboration...
October 29, 2019 16:05 ET | Source: Otonomy, Inc.

Otonomy to Report Third Quarter 2019 Financial Results and Provide Corporate Update

SAN DIEGO, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right